Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

BetterThanBuffett8 Oct. 9 at 9:31 PM

$IMMX They usually don't present shitty data at these conferences, do they? 😜

2 · Reply

Daddy044 Oct. 9 at 5:42 PM

$IMMX stay long, ignore financing rumors, major data point November 3

2 · Reply

ImmxBeliever Oct. 9 at 3:53 PM

$IMMX Daddy is so happy More news coming. Cheers

1 · Reply

keebs107 Oct. 9 at 2:59 PM

$IMMX

0 · Reply

Nwagn Oct. 9 at 1:19 PM

$IMMX

0 · Reply

BOXLinvestor Oct. 9 at 5:14 AM

$IMMX Immix Biopharma (stock volume 10-08-25) 2.54 +1.2% | volume 1,493,429 | 90-day avg 241,517 × 6.2

0 · Reply

LiquidThetaLEAPS Oct. 9 at 4:17 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IMMX Current Share Price: $2.46 Contracts: $IMMX May 15, 2026 $2 Calls Scale in: $0.91- $1.11 Scale out: $1.42-$1.82 Can Easily Capture: 60% ROI Blended DTE: 220 Days | Join Elites here: https://liquidtheta.com/

0 · Reply

Daddy044 Oct. 9 at 4:06 AM

$IMMX its all about data. Im buying dips and holding. November 3 is a big day.

0 · Reply

ImmxBeliever Oct. 8 at 8:23 PM

$IMMX This dude has nearly 20K followers He’s done his research Cheers

0 · Reply

PMtrader_92 Oct. 8 at 8:16 PM

$IMMX I’m bearish and bullish

0 · Reply

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Oct 1, 2025, 8:45 AM EDT - 8 days ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 21 days ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Sep 11, 2025, 9:15 AM EDT - 4 weeks ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Sep 8, 2025, 4:05 PM EDT - 4 weeks ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 6 weeks ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 6, 2025, 12:30 PM EDT - 2 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

Jul 11, 2025, 9:36 AM EDT - 3 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 3 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 4 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 4 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 4 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 5 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 5 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 6 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 8 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 9 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 10 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 10 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 10 months ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 10 months ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 11 months ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 1 year ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 1 year ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 1 year ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 1 year ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 1 year ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 8:35 AM EST - 1 year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Dec 18, 2023, 9:39 AM EST - 1 year ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

$Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023$

Dec 11, 2023, 9:36 AM EST - 1 year ago

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Dec 3, 2023, 2:02 AM EST - 2 years ago

Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

Nov 30, 2023, 9:46 AM EST - 2 years ago

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

$Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis$

Nov 22, 2023, 9:19 AM EST - 2 years ago

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Nov 21, 2023, 9:46 AM EST - 2 years ago

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

$Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients$

Nov 6, 2023, 9:12 AM EST - 2 years ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

$Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients$

Nov 6, 2023, 8:40 AM EST - 2 years ago

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Oct 26, 2023, 8:58 AM EDT - 2 years ago

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Oct 16, 2023, 9:05 AM EDT - 2 years ago

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

BetterThanBuffett8 Oct. 9 at 9:31 PM

$IMMX They usually don't present shitty data at these conferences, do they? 😜

2 · Reply

Daddy044 Oct. 9 at 5:42 PM

$IMMX stay long, ignore financing rumors, major data point November 3

2 · Reply

ImmxBeliever Oct. 9 at 3:53 PM

$IMMX Daddy is so happy More news coming. Cheers

1 · Reply

keebs107 Oct. 9 at 2:59 PM

$IMMX

0 · Reply

Nwagn Oct. 9 at 1:19 PM

$IMMX

0 · Reply

BOXLinvestor Oct. 9 at 5:14 AM

$IMMX Immix Biopharma (stock volume 10-08-25) 2.54 +1.2% | volume 1,493,429 | 90-day avg 241,517 × 6.2

0 · Reply

LiquidThetaLEAPS Oct. 9 at 4:17 AM

0 · Reply

Daddy044 Oct. 9 at 4:06 AM

$IMMX its all about data. Im buying dips and holding. November 3 is a big day.

0 · Reply

ImmxBeliever Oct. 8 at 8:23 PM

$IMMX This dude has nearly 20K followers He’s done his research Cheers

0 · Reply

PMtrader_92 Oct. 8 at 8:16 PM

$IMMX I’m bearish and bullish

0 · Reply

keebs107 Oct. 8 at 6:03 PM

$IMMX $40 PPS please

0 · Reply

BearishAlgo Oct. 8 at 5:30 PM

$IMMX Rejected the zone, never broke the upper boundary, dropped from 2.85 down to 2.36, closed at 2.55, no news

0 · Reply

Blu3sapphire1007 Oct. 8 at 4:59 PM

$IMMX congrats bulls!!! Saw this at $1.97 3 days ago. Nice gains!!!!! Will wait for a dip. Good luck everyone

0 · Reply

eddiez69 Oct. 8 at 4:40 PM

$IMMX This is easily a $200M to $400M market cap making it a potential $6 to $12 stock in the near-term. Check out $CASI also - its trading with just $30M market cap now with just 16M shares in the float- this is another one that could 3x to 5x in price

1 · Reply

Nwagn Oct. 8 at 4:38 PM

$IMMX let it run

0 · Reply

ImmxBeliever Oct. 8 at 4:16 PM

$IMMX 3 2 1 Watch in 2 mins

0 · Reply

ImmxBeliever Oct. 8 at 3:42 PM

$IMMX More and more eyes 55K followers

0 · Reply

tutmose Oct. 8 at 11:58 AM

$IMMX Seems there was a leak yesterday that the company was going to release news. In fact the leak must have been from couple of days ago. I wonder why the SEC doesn't check for possible insider information. Well the news came out few minutes after the market closed and it was exactly same news as the day before and this is why the stock sold off from above $2.90 back to $2.50. I guess it might go down a little more today.

1 · Reply

ImmxBeliever Oct. 8 at 3:30 AM

Lots of 👀👀👀 $IMMX Tomorrow should be good

0 · Reply

Nwagn Oct. 8 at 2:41 AM

$IMMX overnight trading 2.62. Crossing fingers here

0 · Reply

ImmxBeliever Oct. 8 at 12:07 AM

$IMMX Something big is about to happen. There is new Investor friendly website: http://IMMXStock.com It’s great. Check out the key slides Since they don’t need cash, something is up

1 · Reply

Daddy044 Oct. 7 at 10:29 PM

$IMMX Long undervalued and finally regaining momentum. Be wary of fake news or attempts to reverse the stock gains. Now we know IMMX is presenting at ASH wait for the Abstract to be released on November 3!

0 · Reply

Market Cap	83.91M
Revenue (ttm)	0.00
Net Income (ttm)	-21.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	560,900
Avg Vol	283,168
Day's Range	N/A - N/A
Shares Out	33.04M
Stochastic %K	71%
Beta	0.23
Analysts	Sell
Price Target	$8.00